Abstract
The objective of this study was to review available health economic evaluations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. These drugs reduce low-density lipid cholesterol levels and cardiovascular risk, but their cost effectiveness has been questioned. We searched Medline and Embase for economic evaluations in any language at any time. Studies were included if they analysed any PCSK9 inhibitor compared with either statin alone or in combination with ezetimibe or any other therapy considered standard prior to the introduction of PCSK9 inhibitors. We found ten full health economic evaluations of PCSK9 inhibitors, two from Europe and eight from the United States (US). Six of the eight from the US were from two different consortia that analysed PCSK9 inhibitors at different stages through the development of evidence. All studies generally reported incremental cost-effectiveness ratios above suggested thresholds for cost effectiveness, except one study from Spain. The results of this review indicate that PCSK9 inhibitors in general are not cost effective at the current prices, but lower prices may change the results.
Similar content being viewed by others
References
World Health Organization. WHO Mortality database. http://www.who.int/healthinfo/mortality_data/en/. Accessed 23 Dec 2017.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058.
Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2017;35(5):537–47.
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99.
Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–82.
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.
Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.
European Medicines Agency. European Public Assessment report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003766/WC500191398.pdf. Accessed 21 Dec 2017.
Hawkes N. Evolocumab, “must become cheaper” to be cost effective in enhancing benefits of statins. BMJ. 2017;358:j4042. https://doi.org/10.1136/bmj.j4042.
Norwegian Medicines Agency. [Reimbursement report—Alirocumab for treatment of hypercholesterolemia] In Norwegian. 08.06.2016. https://legemiddelverket.no/Documents/Refusjon%20og%20pris/Helse%C3%B8konomiske%20rapporter/P/Praluent_hyperkolesterolemi_2016.pdf. Accessed 4 May 2018.
Drummond M (2015) Methods for the economic evaluation of health care programmes, 4th edn, vol. xiii. Oxford University Press, Oxford, pp. 445.
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069–78.
Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313–20.
Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther. 2017;39(4):771–786 e3.
Cholesterol treatment trialists collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
Korman M, Wisløff T. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. Eur Heart J Cardiovasc Pharmacother. 2018;4(1):15–22. https://doi.org/10.1093/ehjcvp/pvx010.
Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA. 2017;318(8):748–50.
Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743–53.
Tice JA, Ollendorf DA, Chapman R, Kumar V, Seidner M, Rind DM, Pearson SD. Evolocumab for treatment of high cholesterol: effectiveness and value. ICER-report September 11, 2017.
Tice JA, Ollendorf DA, Cunningham C, Pearson SD. PCSK9 Inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks. ICER-report 2015.
Arrieta A, Page TF, Veledar E, Nasir K. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One. 2017;12(1):e0169761.
Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol. 2017.
Peñaloza-Ramos MC, Jowett S, Sutton AJ, McManus RJ, Barton P. The importance of model structure in the cost-effectiveness analysis of primary care interventions for the management of hypertension. Value Health. 2017 [Published online 19.10.2017].
Claxton K, Martin M, Soares M, Rice N, Spackman E, Hinde S, Devlin N, Smith PC, Sculpher M. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1–503.
Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929–35.
Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A, Simon A. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51.
Wisløff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. Pharmacoeconomics. 2014;32(6):601–12.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527–39.
Woods B, Faria R, Griffin S. Assessing the value of new treatments for hepatitis C: are international decision makers getting this right? Pharmacoeconomics. 2016;34(5):427–33.
Acknowledgements
All authors drafted and revised the manuscript and approved the last version. MJK and TW conducted the search for articles, decided which articles to include, read all articles and summarized them.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The present analysis received no funding and was entirely undertaken by the authors during their regular work hours and/or leisure time.
Conflicts of interest
No funding was received to conduct the work. Mr Korman reports no potential conflicts of interest. Dr Retterstøl reports personal fees and grants from Oslo Economics, Sanofi, Amgen, Achea, Mills DA, Norwegian Directorate of Health, Norwegian Medical Association, MSD and Sunovion in the Nordic Region. Dr Kristiansen reports funding from Amgen through Oslo Economics. Dr Wisløff reports personal fees from Amgen through Oslo Economics.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Korman, M.J., Retterstøl, K., Kristiansen, I.S. et al. Are PCSK9 Inhibitors Cost Effective?. PharmacoEconomics 36, 1031–1041 (2018). https://doi.org/10.1007/s40273-018-0671-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40273-018-0671-0